Number of botulinum toxin injections needed to stop requests for treatment for chronic lateral epicondylar tendinopathy. A 1-year follow-up study

Cogné, Michel; Creuzé, A.; Petit, H; Delleci, C.; Dehail, Patrick; Seze, M. De

doi:10.1016/j.rehab.2018.12.003

Cited by 15 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results showed that patients in the G1, G2, and G3 groups had a significantly better quality of life, reduced pain, and maximum grip strength than the G0 group, with significantly less impact on daily and business activities. Therefore, 1 to 2 injections of 40 U BTX-A were more effective in treating chronic lateral epicondylitis (Cogné et al, 2019). In addition, other studies have also analyzed the effect of different site injections of BTX-A on the efficacy of treatment of lateral N a t u r a l R e s o u r c e f o r H u m a n H e a l t h 2021, , 1-7 | 2 On day 60, the BTX-A combined with the LA group did not show any significant difference in PGI-I from the LA injection alone group, but both groups showed an overall improvement in pain.…”

Section: Lateral Epicondyli Smentioning

confidence: 99%

Advances in botulinum toxin type A for the treatment of pain

Jiang¹,

Huang²,

Yang³

et al. 2021

NRFHH

View full text Add to dashboard Cite

<i>Clostridium botulinum</i> (CB) is a Gram-positive anaerobic bacterium and a significant cause of food spoilage. Foodborne botulism occurs worldwide every year and even lead to death from respiratory distress in severe cases after eating botulism-contaminated food. The pathogenicity of CB lies in its ability to produce a potent neurotoxin, “botulinum toxin (BTX)”, for which eight different subtypes have already been isolated so far. Botulinum toxin type A (BTX-A) is widely used to treat critical clinical issues due to its good affinity and tolerability. Studies have shown that BTX-A injections effectively treat myofascial pain, inflammatory pain, and neuropathic pain. The current article mainly reviews the latest research progress using BTX-A in pain treatment during two years.

show abstract

Section: Lateral Epicondyli Smentioning

confidence: 99%

Advances in botulinum toxin type A for the treatment of pain

Jiang¹,

Huang²,

Yang³

et al. 2021

NRFHH

View full text Add to dashboard Cite

show abstract

“…Hinsichtlich der Fragen nach der Dauer des Effektes über die Beobachtungszeit in den genannten Studien von 3-4 Monaten hinaus und des Effektes einer 2. Injektion verweisen wir auf eine weitere neue Studie von Cogné et al [32]. In dieser Arbeit wurde die Studie der Arbeitsgruppe aus dem Jahr 2018 [17] fortgeführt: Die 29 Probanden der Therapiegruppe mit primär erfolgter Botu-linumtoxininjektion und die 21 Probanden der Kontrollgruppe mit nachträglicher Infiltration mit Botulinumtoxin in der beschriebenen Technik nach 90 Tagen (n = 48), 180-270 Tagen (n = 48) und nach einem Jahr (n = 24) wurden weiterverfolgt.…”

Section: Schlussbetrachtungunclassified

Botulinum Toxin for Chronic Lateral Epicondylitis (LE)

Grüner¹,

Schulz²,

Schlüter-Brust

et al. 2020

Z Orthop Unfall

View full text Add to dashboard Cite

Lateral epicondylitis is a common disease in orthopaedic practice. Although the majority of cases do not become chronic, patients who do not respond to the initial treatment may suffer from pain in the long term and effective treatment is challenging. The off-label use of botulinum toxin is one of the common potential indications for the substance in orthopaedics and traumatology. In a literature review of 2000 – 2019, eight EBM ≥ level 3 studies evaluating the use of botulinum toxin in lateral epicondylitis were found. Five of these studies evaluated botulinum toxin versus placebo in chronic cases; two other studies compared botulinum toxin with corticosteroids in acute cases and classic Hohmann surgery in chronic cases; the eighth study compared botulinum toxin in two different injection sites and corticosteroids by classic injection. Our findings suggest that the use of this substance may be a treatment option in refractory chronic cases before surgery is indicated. The working group on botulinum toxin in O & T of the International Musculoskeletal Pain Society (IMPS/IGOST) introduced an alternative injection schedule, which combines findings from the recent clinical literature with practical experience in order to reduce the risk of side effects while ensuring treatment effectiveness. Using 2 simple tests of function and, if necessary, sonographic verification, 2 separate injection sites in the extensor carpi radialis or the extensor digitorum can be identified by palpation. The tendon level on the lateral epicondyle acts as the third injection site. With optimal use of the ampoule content, the 3 injection sites can be infiltrated individually, depending on the muscle status. On the one hand, this enables treatment to take place after a dual therapy approach and, on the other hand, the risk of overdose in a muscle with subsequent unnecessary muscle weakening can be reduced.

show abstract

“…The use of botulinum toxin induces spontaneous repair of the affected extensor tendon during a temporary period of rest and paralysis of the extensor muscle, and decreases pain perception by releasing cellular mediators such as substance P, glutamate, and bradykinin [ 21 ]. Several previous studies have demonstrated favorable long-term clinical outcomes in pain and clinical scores after administering botulinum toxin in refractory chronic lateral epicondylitis, as compared to analgesics, physiotherapy, electrotherapy, and peritendinous injection treatment; botulinum may therefore be an alternative treatment modality in potential patients for surgical intervention [ 12 , 22 ]. Moreover, hyaluronic acid, one of the main components in synovial fluid cartilages and tendon extracellular matrix, is naturally produced in the tendon sheath, and has proven to yield beneficial effects in pain relief and functional improvement after articular administration in osteoarthritis and soft tissue injuries [ 23 ].…”

Section: Current Updates On Interventional Therapy With Injectionmentioning

confidence: 99%

“…A study on the long-term efficacy of ATI treatment with a follow-up period of more than 4 years, reports symptomatic and functional improvement without adverse effects, complications, or infections in >70% participants. However, ATI treatment is still being explored with animal studies and preclinical trials, and requires further researches with a larger study population to determine the efficacy and safety ( Table 1 ) [ 22 , 26 , 28 - 34 ].…”

Section: Current Updates On Interventional Therapy With Injectionmentioning

confidence: 99%

Current Trends for Treating Lateral Epicondylitis

Kim

Yoo

Choi

et al. 2019

Clin Shoulder Elbow

View full text Add to dashboard Cite

Lateral epicondylitis, also known as ‘tennis elbow’, is a degenerative rather than inflammatory tendinopathy, causing chronic recalcitrant pain in elbow joints. Although most patients with lateral epicondylitis resolve spontaneously or with standard conservative management, few refractory lateral epicondylitis are candidates for alternative non-operative and operative modalities. Other than standard conservative treatments including rest, analgesics, non-steroidal anti-inflammatory medications, orthosis and physical therapies, nonoperative treatments encompass interventional therapies include different types of injections, such as corticosteroid, lidocaine, autologous blood, platelet-rich plasma, and botulinum toxin, which are available for both short-term and long-term outcomes in pain resolution and functional improvement. In addition, newly emerging biologic enhancement products such as bone marrow aspirate concentrate and autologous tenocyte injectates are also under clinical use and investigations. Despite all non-operative therapeutic trials, persistent debilitating pain in patients with lateral epicondylitis for more than 6 months are candidates for surgical treatment, which include open, percutaneous, and arthroscopic approaches. This review addresses the current updates on emerging non-operative injection therapies as well as arthroscopic intervention in lateral epicondylitis.

show abstract

Number of botulinum toxin injections needed to stop requests for treatment for chronic lateral epicondylar tendinopathy. A 1-year follow-up study

Cited by 15 publications

References 37 publications

Advances in botulinum toxin type A for the treatment of pain

Advances in botulinum toxin type A for the treatment of pain

Botulinum Toxin for Chronic Lateral Epicondylitis (LE)

Current Trends for Treating Lateral Epicondylitis

Contact Info

Product

Resources

About